Author
Listed:
- Martina Cardenas
(Universidad Abierta Interamericana, Facultad de Medicina y Ciencias de la Salud, Carrera de Medicina. Ciudad Autónoma de Buenos Aires, Argentina)
- Gabriela Cavillon
(Universidad Abierta Interamericana, Facultad de Medicina y Ciencias de la Salud, Carrera de Medicina. Ciudad Autónoma de Buenos Aires, Argentina)
Abstract
Backgroud: Merkel cell carcinoma is a cutaneous tumor, also known as neuroendocrine carcinoma, that is infrequent and highly aggressive, with a high mortality rate. 1 It primarily affects individuals over 60 years of age, those with immunosuppression, or those infected with the polyomavirus (MCPyV). It is an underdiagnosed tumor due to the nonspecificity of its clinical and dermatological manifestations. The definitive diagnosis is made by histopathological study, with identification of the sentinel lymph node being essential, since the presence of metastases is associated with a significant decrease in five-year survival. Although there is no optimal treatment, surgery remains a therapeutic pillar, complemented by radiotherapy and immunotherapy as adjuvant treatments. Material And Methods: The study was conducted using a mixed-method design, comprising a descriptive literature review conducted in scientific databases (PubMed, SciELO, Cochrane Library, and Elsevier), prioritizing recent population-based studies addressing the incidence, mortality, and survival associated with Merkel cell carcinoma. This was complemented by clinical follow-up of a 55-year-old female patient diagnosed with the condition in 2021. Results: The patient consulted on 06/25/2021 for a painless red nodule in an exposed region. The diagnosis was confirmed by biopsy on 01/07/2021. Despite the treatment, he developed lymph node and distant metastases and died in 2023. The revised bibliography shows a low overall survival, especially in advanced stages. Conclusion: The CCM continues to be an underdiagnosed neoplasm. Its early detection is key to improving prognosis and increasing survival. Despite the early diagnosis, the patient did not exceed three years of survival, which shows that the CCM can have aggressive clinical behavior even in the initial stages.
Suggested Citation
Handle:
RePEc:cwh:ijneur:v:59:y:2025:id:239
DOI: 10.62486/ijn2025239
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:cwh:ijneur:v:59:y:2025:id:239. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Dr. Andrew Alberto López Sánchez (email available below). General contact details of provider: https://ijneurology.org/index.php/ijn .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.